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Cost of rotavirus diarrhea for programmatic
evaluation of vaccination in Vietnam
Arthorn Riewpaiboon1* , Sunheang Shin2,3, Thi Phuong Mai Le4, Dinh Thiem Vu4, Thi Hien Anh Nguyen4,
Neal Alexander2, Duc Anh Dang4 and the Rotavirus Economic Study Group
Abstract
Background: Rotavirus is the most common etiology of diarrhea-associated hospitalizations and clinic visits in
Vietnamese children < 5 years old. To estimate the economic burden of rotavirus-associated formal healthcare
encounters, an economic study was conducted.
Methods: A cost-of-illness study was performed from a societal perspective. Data were collected from children
below the age of five years who presented to a clinic or hospital with symptoms of acute gastroenteritis (AGE).
Patient-specific information on resource use and cost was obtained through caregiver interviews and medical
chart review. Costs are presented in 2014 US dollar ($).
Results: A total of 557 children with symptoms of AGE were enrolled from March through June 2009, with mean
age of 16.5 months. Of the 340 outpatients and 217 admitted patients enrolled, 41 % tested rotavirus positive. It
was found that, from a societal perspective, the mean total cost of AGE was $175. Costs of patients with and
without rotavirus were $217 and $158, respectively. From multiple regression analysis, it was found that rotavirus
infection, patient age and receiving oral rehydration solution before visiting health facility had significant effect
on the costs.
Conclusions: This study clearly demonstrated substantial economic burden of AGE including rotavirus disease.
They were significantly greater than the previously reported cost estimates in Vietnam. These updated costs of
illness result in more favorable vaccine cost-effectiveness than in previous economic evaluations.
Keywords: Rotavirus burden, Acute gastroenteritis, Cost of illness, Vietnam
Background
Rotavirus infection is a major reason for hospitalization
and clinic visits among children under five years of age,
with a significant impact on utilization of health care
resources and costs, both in developed and developing
countries [1–3]. Recently, two rotavirus vaccines have
been licensed globally but neither has been adopted in
the routine immunization program in the majority of
developing countries. Decisions concerning the addition
of new vaccines to national immunization program are
driven by scientific, political, economic, and logistic
considerations [4]. Key factors influencing such a policy
decision include the economic burden of disease on
health care system and society and the cost-effectiveness
of a new immunization program. The cost-effectiveness
of rotavirus vaccines has been evaluated more widely
over the past decade [5]. In Vietnam, several groups
have published the cost effectiveness of rotavirus vaccine
[3, 6–8]. All the previous studies on the cost-effectiveness
of rotavirus vaccine were based on the same cost estimates
of rotavirus disease from the earliest study by Fischer et al.
[3] which, as its authors acknowledged, had limitation in
its assumptions and methodologies [3]. First, patient-
specific data were obtained retrospectively by interviewing
families of historical patients, in which recall bias could
not be excluded. Second, per bed-day and per-visit costs
were estimated based on the opinions of regional health
experts rather than a properly designed institutional
costing study. Third, costs were estimated for historical
diarrheal patients without confirmed rotavirus etiology.
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Last, data were collected from the patients recruited in
one province, making it problematic, as it is not repre-
sentative of nationally. Aiming to update knowledge of
the country’s burden of rotavirus disease, we performed
a cost-of-illness study in three provinces of Vietnam,
based on prospective study of rotavirus patients. In
addition, we demonstrated how to use the costs in eco-
nomic evaluation of vaccination program.
Methods
Study design
This study was designed as an incidence-based, cost-of-
illness study from a societal perspective. An incidence-
based approach considers only the newly occurring cases
within a study period and follows them during the entire
course of each episode. Costs were measured based on a
micro-costing approach [9, 10]. This study was nested in
a rotavirus surveillance project, which was performed in
three provinces of Vietnam during 2009.
Study population and sites
Vietnam is a developing country in Southeast Asia with
a long coastline on the South China Sea, stretching
more than 2400 km from a temperate climatic zone in
the north to a subtropical climate in the South. The
population of 89.71 million (according to the census in
April 2012) includes an annual birth cohort of 1.7 million
with an infant mortality rate of 15.3 per 1000 live births in
2013 [11]. The study was carried out in three provinces
representing the Northern, Northeastern and Southeastern
regions. Vinh Phuc in the Red River delta of Northern
Vietnam, population 1.0 million; Hai Phong in the
Northeastern coastal area, population ~1.9 million;
and Khanh Hoa in the Southeastern coastal area, popu-
lation 1.1 million. For both the rotavirus surveillance and
the cost-of-illness studies, cases with symptoms of acute
gastroenteritis (AGE) were enrolled among children aged
less than 5 years and living in one of the five catchment
areas of three provinces in Vietnam: Nha Trang city in
Khanh Hoa Province, Vinh Yen city and Bin Xuyen district
in Vinh Phuc province, and Kien An and Le Chan districts
in Hai Phong. Catchment areas were selected considering
the balance of geographic location and economic level in
order to make data more representative of the whole
country. It was also considered whether a population
could easily be defined in terms of health care utilization
pattern and was relatively stable. We invited all hospi-
tals and major outpatient clinics that were known to
serve pediatric diarrheal patients in each of the five
catchment areas.
Sample size
In order to obtain more accurate and representative
cost estimates, patients were divided into groups based
on the suspected cost predictors, including geographical
location (province), type of patient care (inpatient, out-
patient), type of facilities (private clinic, polyclinic, hos-
pital), rotavirus in stool, patients receiving oral rehydration
solution prior to institutional treatment, patients receiving
breastfeeding, and child’s age. Stratified by a combination
of predictor variables, at least 30 cases are needed for each
patient-group [12]. Thus, we targeted at least 330 AGE
episodes to be enrolled for this economic study.
Definition
In this study, total cost of illness is defined as the sum of
direct cost and indirect cost (the cost of productivity loss)
starting from the onset of illness through the end of each
episode. Thus, information was collected on all resource
uses incurred at any health care provider/service before
and after presentation to a study site, together with the re-
sources used at the study facility. Direct costs are defined
as direct medical and direct non-medical costs. Direct
medical cost is the sum of treatment costs. Direct non-
medical costs are for travel and meals. Indirect cost is
defined as time lost by caregivers due to the child’s
illness, because patients in this study are not of working
age [13, 14]. Hence, caregiving time was calculated as
the number of person-days that parents and/or family
members spent on providing care for the sick child.
Data and stool collection
Treatment costs prior to and after the presentation to a
study site were based on the expenditure information
obtained from caregiver interviews. The treatment costs
at a study site (except for private clinics) were the sum
of the cost of routine services at OPD/IPD, costs of
medicines, and laboratory investigation costs.
Dedicated staff reviewed the address and age of each
AGE patient upon presentation in order to check eligi-
bility. Once written informed consent was obtained from
parents/guardians, information was collected through
caregiver interview and medical chart reviews. A pre-
structured questionnaire was used in interviewing care-
givers to collect demographic information and history
of healthcare utilization (e.g. type of facilities where
admitted or treated, and duration of stay or frequency
of visit). Any out-of-pocket expenses that incurred during
the course of each episode were ascertained by asking
caregivers, and included treatment cost, transportation
fee, and cost of meal and/or accommodation. The total
time spent for caring for the sick child by all caregivers
was collected to calculate time cost (or productivity loss).
Trained staff reviewed medical records to extract the rele-
vant data on medical resource uses, then recorded them
on a standardized case report form. Information collected
included the list and quantity of medicines, laboratory
tests, and the number of days hospitalized. Family
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members were followed up every three days after dis-
charge until the recovery of each episode was confirmed.
A bulk stool specimen was collected from each patient
in a standardized stool container. Within 48 h of collec-
tion, stool specimens were transported to the referral loca-
tion. Once a week, specimens were sent to the National
Institute for Hygiene and Epidemiology (NIHE) in Hanoi
and tested for rotavirus antigen by enzyme immunoassay
(EIA) test using a commercial kit (DAKO, UK) under the
standard operating procedure [15].
Costing methods
Unit costs of laboratory tests and routine services were
extracted from a facility-based institutional costing study
performed in Khanh Hoa province [16]. The costs in-
cluded material, labor and capital costs. Unit prices were
adjusted by the ratio of cost to charge, resulting in unit
costs for this study. These ratios were 1.18 and 1.17 for
polyclinics (public clinics) and hospitals, respectively
[16]. Treatment costs at a private clinic were based on
the charged prices. Caregivers’ time costs were calculated
according to the reference wage: 88,380 Vietnamese Dong
(VND) per day [17]. The cost of rotavirus antigen testing
was not included because it was a part of surveillance
project (not routine practice).
Costs were estimated under the assumptions of two
models: Model A classified the time loss of caregivers as
indirect cost (base case) and Model B classified it as
direct non-medical cost [9, 10]. All costs were originally
calculated in 2009 Vietnamese Dong (VND). They were
converted to 2014 values by the consumer price index of
medicine and health care (2009 = 100, 2014 = 195.08)
[17]. Finally, they were converted to US dollars ($) using
the exchange rate of $1.00 = 21,130.5 VND [18].
Data management and analysis
Data were double entered into a custom-made database,
using Microsoft Visual FoxPro Software 9.0 platform
and then exported into Microsoft Excel for verification
and further analyses. IBM SPSS Statistics version 21 was
used for statistical analysis [19]. Descriptive statistics were
used to summarize study variables. The costs were log-
transformed to meet the assumption of normal distribution.
Model checks included linearity, normal distribution,
multi-collinearity, influential observations, and outliers [20].
To obtain adjusted estimates of the effect of rota-
virus on costs, stepwise multiple regression analysis
was employed [20]. Independent variables with prob-
ability values of F statistics ≤ 0.05 were entered. Sensi-
tivity analysis was conducted to measure the effect of
cost classification; Models A and B, classifying costs of
caregiver time (informal care) as indirect and direct,
respectively. In addition, the costs were measured
based on different economic evaluation methods.
Results
From March till June 2009, 557 episodes were included
in the analysis. Characteristics of patients are presented
in Table 1. Forty-one percent of AGE patients had rota-
virus in stool (positive EIA test) and the average patient
Table 1 Characteristics of patients
Rotavirus in
stool
Total
No Yes
Age (month) Mean 16.67 15.63 16.51
Median 12.00 13.00 13.00
Gender; female Female 137 95 232
59.1 % 40.9 % 100.0 %
Male 192 133 325
59.1 % 40.9 % 100 %
Child primarily
breastfed; yes
Yes 306 213 519
59.0 % 41.0 % 100.0 %
No 21 14 35
60.0 % 40.0 % 100 %
Receiving oral rehydration
solution before visiting
the study facilitya; yes
Yes 78 88 166
47.0 % 53.0 % 100.0 %
No 250 140 390
64.1 % 35.9 % 100 %
Health facility typea Private clinic 33 16 49
67.3 % 32.7 % 100.0 %
Polyclinic 97 53 150
64.7 % 35.3 % 100.0 %
Hospital
outpatient
102 39 141
72.3 % 27.7 % 100.0 %
Hospital inpatient 97 120 217
44.7 % 55.3 % 100.0 %
Type of patienta Outpatient 232 108 340
68.2 % 31.8 % 100.0 %
Inpatient 97 120 217
44.7 % 55.3 % 100.0 %
Provincea Hai phong 106 69 175
60.6 % 39.4 % 100.0 %
Vinh phuc 140 55 195
71.8 % 28.2 % 100.0 %
Nha trang 83 104 187
44.4 % 55.6 % 100.0 %
Total 329 228 557
59.1 % 40.9 % 100.0 %
aSignificant difference; Chi-Square Tests at p < 0.05
Riewpaiboon et al. BMC Public Health  (2016) 16:777 Page 3 of 7
age was 16.5 months. Comparing patients with and
without rotavirus in stool, there was no statistically sig-
nificant difference in terms of age, gender, or receiving
primarily breast milk. However, there were differences in
the proportion rotavirus positive in terms of prior re-
ceipt of whether oral rehydration solution had been
given prior to presentation (53.0 % rotavirus positive) or
not (35.9 %). Similarly, inpatients were more likely to be
rotavirus-positive (55.3 %) than outpatients (31.8 %).
Resource utilization and costs are presented in Table 2.
Caregiving days of parents or relatives of patients with
rotavirus were statistically significantly higher than those
of patients without rotavirus. Again, direct medical cost,
direct cost, indirect cost and total cost of illness of pa-
tients with rotavirus were statistically higher than those
of those without rotavirus. Only direct non-medical
cost (not including cost of caregiver time) was not sta-
tistically significantly different. Costs of patients with
rotavirus-positive were higher than those of rotavirus-
negative in all age groups. Older patients had lower
costs than younger patients, whether rotavirus-positive
or-negative (Table 3). To confirm the effect of rotavirus
on costs, multiple regression analysis was conducted.
Rotavirus status and other potential predictors of direct
medical cost, direct cost and total cost of illness are in
Table 4. Fitted models are presented in Table 5. The
models include rotavirus in stool, age and receiving
ORS. Power of explanation (adjusted R2) was in range
of 7–13 %.
Table 6 shows the sensitivity of the results to model
choice. Model A is the base case, with informal care
costs classified as indirect, rather than direct non-
medical (Model B). Both models were used to estimate
cost-effectiveness in terms of a) case avoided or life
saved, and also b) years of life gained. In societal-
perspective cost-utility analysis (CUA), only direct costs
are included [21]. Direct costs are necessarily higher
when they are defined more widely to include informal
care (Model B) and, in turn, this increases the incremental
cost-effective ratio (ICER), of which cost is the numerator.
Hence, differences in classifying informal costs care have
affected the economic evaluation results.
Discussion
Focusing on the cost of rotavirus diarrhea in Southeast
Asia, studies in Indonesia, Malaysia and Vietnam have
been published in international journals [3, 22–24]. In a
study conducted in Indonesia in 2007 [22], parents of
1349 patients were interviewed during outpatient visits,
while inpatients were interviewed on discharge and
again two weeks later. The study covered direct medical
costs, direct non-medical costs and indirect costs (time
taking care of sick children). Direct medical costs were
based on actual payments made by the patients. In
Malaysia, Lee et al. (2002) measured the cost of inpa-
tients from a hospital perspective. Three hundred and
ninety-three patients were included in the study. The
costs included were treatment costs or direct medical
costs, covering only patient service departments. Costs
of supporting departments (e.g. administration) were not
included [23]. Another study conducted in Malaysia
during August 2006 and July 2007 measured out-of-
pocket costs [24]. The study covered 260 patients and
Table 2 Resource utilization and costs (2014 USD)
Rotavirus in stool
No (n = 329, 59.1 %) Yes (n = 228, 40.9 %) Total (n = 557)
Mean Median SE Mean Median SE Mean Median SE
Length of stay of inpatients (days) 5.81 5.00 0.31 5.55 5.00 0.23 5.68 5.00 0.18
Caregiving (person-day)a 7.44 6.00 0.28 9.44 8.00 0.36 8.06 7.00 0.21
Total direct cost (not including informal care)a,b 96.99 42.69 6.67 139.80 129.97 8.14 108.92 49.96 4.84
Total direct medical costa,b 75.12 16.37 6.40 117.71 104.55 7.92 87.13 16.74 4.68
Direct nonmedical cost (not including informal care) 21.87 18.47 1.15 22.09 18.75 1.27 21.79 18.47 0.82
Indirect cost (with informal care)a,b 60.73 48.95 2.32 77.03 65.27 2.97 65.74 57.11 1.73
Total cost of illnessa,b 157.72 97.97 8.17 216.83 196.44 10.37 174.66 107.38 6.06
aStatistically significant difference; Mann-Whitney U Test at P < 0.05
bStatistically significant difference; T-Test of natural log form at P < 0.05
Table 3 Average cost of illness (2014 USD) classified by age,
rotavirus infection and cost component
Agea
(years)
Rotavirus
in stool
Number
of cases
Total direct
medical cost
Total direct
cost
Total cost
of illness
1 No 167 87.74 115.45 181.46
Yes 106 125.11 152.17 231.64
2 No 94 69.78 86.73 147.53
Yes 87 124.75 143.13 222.19
3 No 33 70.78 86.41 140.80
Yes 19 81.64 100.95 172.67
5 No 35 33.34 46.43 87.81
Yes 16 73.38 85.94 142.04
ano patient aged 4 years
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included expenses for medical consultations, medica-
tion prior to hospitalization, hospital bills, any special
food or diet, transportation, extra diapers, productivity
loss for caregivers, and other costs incurred by family
members. In Vietnam, a 2003 study enrolled 90 patients
[3] and included direct medical costs, direct non-
medical costs, and indirect costs (time taking care of
sick children). Direct medical costs were estimated per
day and per visit, by interviewing government officials.
For direct non-medical costs and indirect costs, parents
were interviewed.
Due to the different study designs and data limitations,
it was not feasible to directly compare costs between
studies. For direct medical or treatment costs, none of
the previous studies used direct measurement of the
actual costs over the whole hospital (service and sup-
porting departments). This could be a limitation in
terms of economic evaluation from a societal perspec-
tive. Therefore, our study covered both actual and
complete cost of the hospitals with considerable sample
size.
In terms of cost drivers, in addition to rotavirus infec-
tion, it is interesting to notice a similarity between the
study in Canada and our one, namely that age was sig-
nificant predictor variable [25]. The history of receiving
ORS was an additional significant predictor variable in
our analysis (Table 5). In these models, coefficients of
determination indicating power of explanation were small
(0.068–0.129). In the exploration, we fitted a model by
adding health facility types (private clinic, polyclinic and
hospital) and found an increase of the coefficient to 0.885.
However, with significant effect of the facilities, rotavirus
infection did not show the effect. Our interpretation is
that rotavirus infection has effects on the cost but much
less than the types of services at different levels of health
facilities. In real-life practice, rotavirus infection is not
investigated by laboratory test: laboratory investigations
reported here were done as part of the research project.
Therefore, in day-to-day practice, physicians provide
treatment based on clinical symptoms, patient and
health system factors.
In terms of cost driver analysis, we used stepwise
multiple regression analysis. We had limited ability to
validate the model using out-of sample data. Costs are a
major concern in economic evaluation. Reduction in
cost of illness increases net cost and raises the cost-
effectiveness ratio, making the intervention less attractive
economically [26]. As shown in Table 6, we found a
substantially larger cost burden of rotavirus disease in
Vietnam than Fischer et al. in 2004 [3]. The 2014 values of
the 2004 study were USD88, USD18, USD16 and USD21
for in-patients, outpatients at hospitals, polyclinics and
private clinics, respectively. Several factors might have
contributed to this. First, costs were estimated based on
the data collected from patients with rotavirus infection in
Table 4 Potential predictor variables for multiple regression
analysis
Dependent variables
LnDMC Natural log of direct medical cost
LnDC Natural log of direct cost
(not include informal care)
LnTC Natural log of cost of illness
Potential predictor variables
Receiving oral rehydration
solution before visiting the
study facility
Receiving = 1 (30 %), no = 0 (70 %)
Rotavirus in stool Positive = 1 (41 %), negative =0 (59 %)
Child age (months) Mean age in months (16.27)
Child receiving primarily
breastfed
Receiving = 1 (94 %), no = 0 (6 %)
Note: Type of patients and health facility were tested in the model separately
Table 5 Regression models investigating effect of rotavirus
infection on the costs
Predictor variable Unstandardized coefficients
Direct
medical cost
Direct cost Total cost
of illness
Constant 3.437 4.318 4.950
Rotavirus in stool .591 .446 .320
Child age (months) -.020 -.028 -.017
Receiving oral rehydration
solution before visiting the
study facility
.299 n/s .212
Adjusted R2 .068 0.095 0.129
n/s = not statistically significant
Table 6 Cost of rotavirus diarrhea classified by economic
evaluation methods from societal perspective (2014 USD)
Cost by evaluation methods
CEA1a CEA2b CUAc
Model A: Cost of informal care as a part of indirect cost.
1. Direct cost 139.8 139.8 139.8
1.1 Direct medical cost 117.71 117.71 117.71
1.2 Direct nonmedical cost 22.09 22.09 22.09
2. Indirect cost 77.03 n/a n/a
Model B: Cost of informal care as a part of direct nonmedical cost.
1. Direct cost 216.83 216.83 216.83
1.1 Direct medical cost 117.71 117.71 117.71
1.2 Direct nonmedical cost 99.12 99.12 99.12
2. Indirect cost 0 n/a n/a
Notes: aCEA1 = cost-effectiveness analysis in terms of case avoided or
life saved
bCEA2 = cost-effectiveness analysis in terms of life years gained
cCUA = cost-utility analysis in terms of quality-adjusted life year (QALY) or
disability-adjusted life
Year (DALY)
n/a = not applicable; all costs were estimated based on societal perspective
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a prospective manner, whereas the earlier study was based
on historical patients. Second, we followed up each patient
during the entire period of an episode starting from the
onset of disease until the recovery. Nearly one half of the
patients enrolled in our study reported that they had
sought health care prior to presentation to a study health
facility. Relevant costs associated with any health care
utilization prior to or after presentation to a study health
facility were traced, identified, and included in our cost
estimation. Such an intensive follow-up could not have
been made in the previous study since data were obtained
from historical episodes. Third, we calculated unit costs
per clinic visit and per bed day based on an actual study
from Vietnam [16], whereas the previous study was based
on the opinions of local health officials. Last, our study
was based on the data from multiple study sites throughout
three provinces in different regions of Vietnam whereas the
earlier cost estimates were based on the data from one
province [3]. However, a limitation of our study was the
absence of patients with mild symptoms who self-treated
and did not come to the study sites. This limits the
generalizability in terms of economic burden. Information
on the economic burden of an illness is important in setting
priorities, financial and budgeting management, and effi-
ciency management [10]. Cost of illness is a measurement
of an illness’ economic burden on society. Hurdles in
conducting cost-of-illness studies include the absence of
reliable local data, and conceptual or methodological issues
in costing [27]. The latter include controversies in including
productivity cost [28], costing methods (e.g., human capital
approach versus friction cost method [29]), and reference
values (e.g. discount rate [30]). Whether to classify care-
givers’ time as direct non-medical or indirect cost has also
been controversial [10]. The point at issue is double
counting because time cost can be included as either
monetary value or health state (e.g., quality adjusted life
year) [9]. In a review of cost-utility analysis published
during 1976 and 1997, 5.7 % of the papers included
caregiver costs [31]. In a similar economic evaluation, a
study in Thailand classified caregiver costs as direct-
nonmedical [32], while another in Indonesia classified
them as indirect costs [22]. One study omitted mortality
costs, to avoid double counting, but did not mention the
costs of caregiver time loss [33]. Another included them
as indirect costs without identifying their components
[34]. Hodgson concluded that cost-utility analysis from a
societal perspective should exclude indirect costs of
morbidity and mortality (but not that of caregivers) [26].
In summary, previous studies varied in terms of inclusion
and classification of indirect costs in their cost-utility
analysis. This could affect their results in terms of the
incremental cost-effectiveness ratio (ICER). If the ICER is
less than the threshold of willingness-to-pay (for instance,
1 per capita gross domestic product) for the health
intervention evaluated, the intervention is accepted, and
conversely. For instance, in a study on economic evaluation
of varicella vaccination, the vaccine was not acceptable for
a base-case analysis (not including the indirect cost).
However, when the indirect cost was included, the
vaccine is acceptable [35].
WHO guideline recommends that time costs should
be reported separately from other cost estimates in cost
of illness studies. The guideline also recommends that
cost-effectiveness or cost-utility analysis should be con-
ducted both with and without these time costs [14].
Thus, in our analysis, the cost of rotavirus disease was
based on the two different models of cost classification
that caregiver’s time was included as indirect cost versus
non-medical direct costs (Table 6).
Conclusion
This study clearly demonstrated a substantial cost burden
of rotavirus disease to society in Vietnam. This burden was
significantly greater than found previously [3], implying a
more favorable cost effectiveness outcome of rotavirus
vaccination in the country. As the first step, for Vietnam
government’s policy decision on whether to implement
rotavirus vaccination, an economic evaluation of the vac-
cine should be repeated in the Vietnamese context based
on this updated cost information of rotavirus disease.
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